Back to Blog

CoQ10, Melatonin and NAC for Oocyte Quality: What the Evidence Actually Says

Dr. Senai Aksoy · · 9 min read
Medically reviewed on 9 May 2026 — Dr. Senai Aksoy
oocyte qualitycoenzyme Q10melatoninN-acetylcysteineIVF supplements
CoQ10, Melatonin and NAC for Oocyte Quality: What the Evidence Actually Says

TL;DR

CoQ10, melatonin and N-acetylcysteine are the three "egg quality" supplements patients ask about at almost every IVF consultation. The trials show small signals on lab markers — a few more mature oocytes, slightly nicer embryos — but no clean gain in live births. ESHRE did not recommend them as routine add-ons in 2023, and that has not changed in 2025. CoQ10 is worth discussing in poor responders over 40. For everyone else, sleeping properly, eating well, vitamin D and folate carry more weight than any branded bottle.

The bottom line

CoQ10, melatonin, N-acetylcysteine — the three supplements patients bring up at almost every IVF consultation. The randomised trials show small signals on lab markers (a few more mature oocytes, slightly nicer embryo grades), but nothing clean on live births. ESHRE did not endorse them as routine add-ons in its 2023 guidance, and the 2025 updates have not changed that. In a poor responder over 40, CoQ10 is reasonable to discuss. For everyone else, the unglamorous stuff — sleep, a Mediterranean diet, vitamin D, folate — carries more weight than any bottle on the shelf.

What “oocyte quality” actually means

People talk about “oocyte quality” as if it were a score out of ten. In real reproductive biology it is shorthand for three different things, and each one responds to a different lever.

First, meiotic maturity. Only an oocyte that has reached metaphase II can be fertilised. An immature one is set aside in the lab; nothing you swallow the night before will rescue it on the day of the puncture.

Second, chromosomal competence. As a woman ages, her oocytes start to mis-segregate their chromosomes. Around 35, that affects roughly half of the oocytes; by 42, closer to three quarters. This is not a failure of self-care or of clinic-care — it is cellular biology, and it deserves to be said calmly.

Third, mitochondrial health. The oocyte carries the heaviest mitochondrial load of any cell in the human body. Those mitochondria fuel fertilisation and the first divisions of the embryo.

It is precisely this third lever that the supplements are reaching for. On maturity, they have no purchase. On the chromosomal side, they have nothing to offer.

Coenzyme Q10

Coenzyme Q10 (ubiquinone) is a cofactor in the mitochondrial respiratory chain. Levels fall with age, so the rationale is intuitive: top up the precursor and an ageing oocyte may have a little more usable energy.

The most-cited trial is Xu et al. (2018), a randomised study in young women with diminished ovarian reserve. CoQ10 (600 mg/day for 60 days before stimulation) was associated with more retrieved oocytes, more high-quality embryos and a lower cancellation rate. So far, encouraging — but in that same study, and in most that followed, the endpoint that actually matters, live birth, did not move significantly.

That is the structural problem with the entire “egg quality supplement” literature. The intermediate markers shift, the baby in the cot does not. More good-looking embryos without more live births is, in practice, a bit like fitting alloy rims on a car that has no engine.

So an honest read: CoQ10 is biologically plausible, generally well tolerated, and in a difficult-prognosis patient it can be on the table. It is not a treatment for age-related aneuploidy, and on current evidence it is not a fertility drug.

Melatonin

A lot was hoped for here, on the back of melatonin’s antioxidant activity inside the follicle. The first eye-catching paper — Tamura et al., 2008 — reported better fertilisation rates in women given 3 mg/day during stimulation. Predictably, that was enough to launch the trend.

The follow-up has been a lot less tidy. Doses of 3 mg, doses of 6 mg; durations of two weeks, durations of three months; PCOS, poor responders, unselected IVF. Meta-analyses point in different directions depending on which trials they pool. And as with CoQ10, the laboratory signals have not converted into a robust gain in live births.

Worth remembering: melatonin is not inert. Daytime drowsiness and a shifted sleep cycle are real side effects in women taking it without a clear indication.

ESHRE places it in the broader “antioxidant” basket and did not recommend its routine use in ART. The subsequent updates have not promoted it.

N-acetylcysteine (NAC)

NAC is a precursor of glutathione, the cell’s main intracellular antioxidant. It also has insulin-sensitising effects, which is why it was first tested in PCOS rather than as a generic “egg” supplement.

In PCOS specifically, it has been compared head-to-head with metformin. The Cochrane review on insulin sensitisers is clear: NAC sits behind metformin on ovulation, on pregnancy, and on live birth. Put plainly, in PCOS NAC plays a supporting role, not the lead.

For “general oocyte quality” outside PCOS? No agreed dose, no agreed duration, no convincing positive randomised signal, no professional society recommendation. The “NAC for eggs” pitch leans on PCOS data extrapolated to a different question — and those are not the same thing.

So in short: NAC keeps a second-line role in PCOS when metformin is not tolerated. Beyond that, calling it an “egg quality” supplement goes further than the evidence allows.

Where ESHRE has stood in 2023 and 2025

ESHRE published a dedicated good-practice document on add-ons in reproductive medicine in 2023. For CoQ10, melatonin, NAC, and also for vitamin C, vitamin E and selenium, the verdict reads almost identically from one supplement to the next:

The commentaries and updates that followed in 2024 and 2025 have not changed that line. There has been no large pragmatic trial since 2023 that would force a rewrite. When a learned society holds the same position across two consecutive review cycles, the burden of proof sits with whoever wants to step away from it — not the other way around.

Who, in practice, might still consider these?

In real consultations, three patient profiles keep coming up.

The poor responder over 40

Low AMH, a difficult first cycle, very few oocytes on the count. Frankly, this is the only group in which a CoQ10 conversation — typically 200–600 mg/day for 60 to 90 days before stimulation — strikes me as reasonable. The signal is small, the safety is good, the cost and the time-frame stay manageable. I frame it as a possible adjunct, never as a guarantee. And I do not let this kind of side-discussion delay decisions that matter much more: a protocol change, a move to donor oocytes.

The young patient with normal reserve

Here, the biology that CoQ10 is reaching for (mitochondrial decline) is simply not the problem. Spending several hundred euros a month on premium supplements before a first or second IVF attempt is rarely money well placed. Sleep, food and stress repay the same investment far better.

The PCOS patient

NAC is a reasonable conversation when metformin is not tolerated — for the metabolic indication, not to turn the oocyte into a superhero. The mainline treatment remains metformin, or, depending on the protocol, letrozole-based ovulation induction. That is also the line of the international PCOS guideline updated in 2023.

The boring foundations no one wants to talk about

These don’t get marketed because they don’t fit in a glossy bottle. Yet they carry, by some distance, the strongest evidence in fertility medicine:

The supporting literature here is consistent across observational and randomised work, in IVF and in natural conception. None of it will ever look brilliant on a pharmacy shelf — which is exactly why it tends to be undervalued.

Frequently asked questions

Does CoQ10 actually “rejuvenate” eggs?

No, and this needs to be very clear. It can, modestly, support mitochondrial function. It does not reverse the chromosomal errors that underlie age-related infertility. To date, no supplement does.

Is it safe to combine CoQ10, melatonin and NAC before IVF?

Tolerance is generally fine. Benefit is the issue: stacking three supplements does not stack three benefits. No good-quality trial has tested the triple combination on live birth, and the chance of side effects (fatigue, gastrointestinal symptoms, disturbed sleep on melatonin) just goes up.

What dose of CoQ10 was used in the trials?

The IVF trials worked with 200–600 mg/day of ubiquinone or ubiquinol, for 30 to 90 days before stimulation. There is no agreed “optimal” dose, simply because the evidence base is not rich enough to define one.

How long before IVF should you start, if at all?

The biological rationale assumes the supplement is on board during the late stages of follicular development — roughly the two to three months before egg retrieval. Starting a week before stimulation is mostly symbolic.

Are these supplements covered by IVF clinics?

In most countries, no — they are an out-of-pocket cost. That cost is worth weighing against the same money spent on better sleep, a nutrition consult, or simply a less stressful month before stimulation, all of which often pay back more.

When should you be sceptical of an “egg quality” claim?

When it promises a specific number of “rejuvenated years”. When it cites “a study” without naming it. When it blurs the line between lab markers and live births. And when it is sold to you in the same consultation that prescribes the treatment.

Sources

Clinical note

In thirty years of IVF practice, I have watched the supplement aisle expand much faster than the literature that is supposed to justify it. When a patient over 40, with a low AMH and a difficult first cycle, tells me she would like to try CoQ10 before her next attempt, I do not push back — the signal is small, the tolerance is reasonable, and we agree on a defined window.

What I see far too often in clinic is the opposite picture: a couple investing several hundred euros a month in three branded bottles, sleeping five hours a night, eating on the run, arriving at the consultation exhausted, and asking which of the three bottles will save the cycle. None of them will. The same money, redirected toward sleep, food and a calmer month before stimulation, almost always does more for the cycle than the bottles ever will.

— Dr. Senai Aksoy

Dr. Senai Aksoy

Dr. Senai Aksoy studied and trained in France before returning to Turkey, where he helped build the IVF programme at the American Hospital Istanbul. He performed the country's first ICSI procedure in 1994 and has been running his own fertility practice since 1998.

Verified profiles: PubMed ORCID LinkedIn

The content has been created by Dr. Senai Aksoy and medically approved.